These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28588651)

  • 21. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Hammerer PG; Wirth MP;
    Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
    Chrisp P; Sorkin EM
    Drugs Aging; 1991; 1(6):487-509. PubMed ID: 1794035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD
    Malek R; Wu ST; Serrano D; Tho T; Umbas R; Teoh J; Lojanapiwat B; Ong TA; On WK; Thai SM; Kim J; Pophale R; Chiong E
    Transl Androl Urol; 2022 Feb; 11(2):179-189. PubMed ID: 35280654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies.
    Spitz A; Gittelman M; Karsh LI; Dragnic S; Soliman AM; Lele A; Gruca D; Norton M
    Res Rep Urol; 2016; 8():159-64. PubMed ID: 27602344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
    Fowler JE; Flanagan M; Gleason DM; Klimberg IW; Gottesman JE; Sharifi R
    Urology; 2000 May; 55(5):639-42. PubMed ID: 10792069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite.
    Ueno H; Matsuo S
    J Chromatogr; 1991 May; 566(1):57-66. PubMed ID: 1909342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Castration-resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy.
    Yanase A; Sugihara T; Akimoto T; Yokoyama H; Kamei J; Fujisaki A; Ando S; Naoi T; Morita M; Fujimura T
    IJU Case Rep; 2022 Jul; 5(4):251-254. PubMed ID: 35795131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
    Fornara P; Jocham D
    Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
    Kienle E; Lübben G
    Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
    J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
    Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
    Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.
    Merseburger AS; Björk T; Whitehouse J; Meani D
    J Comp Eff Res; 2015 Sep; 4(5):447-53. PubMed ID: 25521079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.
    Lebret T; Rouanne M; Hublarov O; Jinga V; Petkova L; Kotsev R; Sinescu I; Dutailly P
    Ther Adv Urol; 2015 Jun; 7(3):125-34. PubMed ID: 26161143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.